The FDA approved Promega’s OncoMate MSI Dx as a companion diagnostic for Keytruda, helping identify patients with MSI-high solid tumors who may benefit from immunotherapy.
Promega’s OncoMate Test Wins FDA Approval to Identify Solid Tumor Patients Eligible for Keytruda
by | Nov 22, 2026 | Uncategorized | 0 comments

Recent Comments